Marc Bitoun

List of Publications by Year
in descending order

55 papers	7,446 citations	159358 30 h-index	155451 55 g-index
60 all docs	60 docs citations	60 times ranked	15437 citing authors

#	Article	IF	Citations
1	Benefits of therapy by dynamin-2-mutant-specific silencing are maintained with time in a mouse model of dominant centronuclear myopathy. Molecular Therapy - Nucleic Acids, 2022, 27, 1179-1190.	2.3	1
2	BIN1 modulation inÂvivo rescues dynamin-related myopathy. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	10
3	Muscle regeneration affects Adeno Associated Virus 1 mediated transgene transcription. Scientific Reports, 2022, 12, .	1.6	4
4	Satellite cells deficiency and defective regeneration in dynamin 2â€related centronuclear myopathy. FASEB Journal, 2021, 35, e21346.	0.2	7
5	A review of Dynamin 2 involvement in cancers highlights a promising therapeutic target. Journal of Experimental and Clinical Cancer Research, 2021, 40, 238.	3.5	19
6	A DNM2 Centronuclear Myopathy Mutation Reveals a Link between Recycling Endosome Scission and Autophagy. Developmental Cell, 2020, 53, 154-168.e6.	3.1	30
7	Alternative splicing of clathrin heavy chain contributes to the switch from coated pits to plaques. Journal of Cell Biology, 2020, 219, .	2.3	31
8	Correlative SICMâ€FCM reveals changes in morphology and kinetics of endocytic pits induced by diseaseâ€associated mutations in dynamin. FASEB Journal, 2019, 33, 8504-8518.	0.2	21
9	Nuclear defects in skeletal muscle from a Dynamin 2-linked centronuclear myopathy mouse model. Scientific Reports, 2019, 9, 1580.	1.6	17
10	Clathrin plaques and associated actin anchor intermediate filaments in skeletal muscle. Molecular Biology of the Cell, 2019, 30, 579-590.	0.9	40
11	Gene Therapy via Trans-Splicing for LMNA-Related Congenital Muscular Dystrophy. Molecular Therapy - Nucleic Acids, 2018, 10, 376-386.	2.3	29
12	Alleleâ€specific silencing therapy for Dynamin 2â€related dominant centronuclear myopathy. EMBO Molecular Medicine, 2018, 10, 239-253.	3.3	40
13	Reducing dynamin 2 (DNM2) rescues DNM2 -related dominant centronuclear myopathy. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 11066-11071.	3.3	50
14	Loss of Dynamin 2 <scp>GTP</scp>ase function results in microcytic anaemia. British Journal of Haematology, 2017, 178, 616-628.	1.2	7
15	Impaired excitationâ€“contraction coupling in muscle fibres from the dynamin2^{R465W} mouse model of centronuclear myopathy. Journal of Physiology, 2017, 595, 7369-7382.	1.3	22
16	Dynamin-2 mutations linked to Centronuclear Myopathy impair actin-dependent trafficking in muscle cells. Scientific Reports, 2017, 7, 4580.	1.6	37
17	Reprogramming the Dynamin 2 mRNA by Spliceosome-mediated RNA Trans-splicing. Molecular Therapy - Nucleic Acids, 2016, 5, e362.	2.3	10
18	Calcium homeostasis alterations in a mouse model of the Dynamin 2-related centronuclear myopathy. Biology Open, 2016, 5, 1691-1696.	0.6	15

#	Article	IF	Citations
19	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
20	Therapy for Dominant Inherited Diseases by Allele-Specific RNA Interference: Successes and Pitfalls. Current Gene Therapy, 2015, 15, 503-510.	0.9	19
21	Adult-onset autosomal dominant centronuclear myopathy due to BIN1 mutations. Brain, 2014, 137, 3160-3170.	3.7	76
22	Actin scaffolding by clathrin heavy chain is required for skeletal muscle sarcomere organization. Journal of Cell Biology, 2014, 205, 377-393.	2.3	60
23	Role of dynamin 2 in the disassembly of focal adhesions. Journal of Molecular Medicine, 2013, 91, 803-809.	1.7	7
24	Skeletal Muscle Biopsy Analysis in Reducing Body Myopathy and Other FHL1-Related Disorders. Journal of Neuropathology and Experimental Neurology, 2013, 72, 833-845.	0.9	36
25	An alternative mechanism of clathrin-coated pit closure revealed by ion conductance microscopy. Journal of Cell Biology, 2012, 197, 499-508.	2.3	77
26	Mutation spectrum in the large GTPase dynamin 2, and genotype-phenotype correlation in autosomal dominant centronuclear myopathy. Human Mutation, 2012, 33, 949-959.	1.1	115
27	A Centronuclear Myopathy â€“ Dynamin 2 Mutation Impairs Autophagy in Mice. Traffic, 2012, 13, 869-879.	1.3	52
28	Recessive RYR1 mutations cause unusual congenital myopathy with prominent nuclear internalization and large areas of myofibrillar disorganization. Neuropathology and Applied Neurobiology, 2011, 37, 271-284.	1.8	97
29	Centronuclear Myopathies. Seminars in Pediatric Neurology, 2011, 18, 250-256.	1.0	84
30	Phenotype variability and histopathological findings in centronuclear myopathy due to DNM2 mutations. Journal of Neurology, 2011, 258, 1085-1090.	1.8	43
31	Dynamin 2 and human diseases. Journal of Molecular Medicine, 2010, 88, 339-350.	1.7	112
32	Vici syndrome associated with sensorineural hearing loss and evidence of neuromuscular involvement on muscle biopsy. American Journal of Medical Genetics, Part A, 2010, 152A, 741-747.	0.7	40
33	A centronuclear myopathy-dynamin 2 mutation impairs skeletal muscle structure and function in mice. Human Molecular Genetics, 2010, 19, 4820-4836.	1.4	107
34	PHENOTYPE OF A PATIENT WITH RECESSIVE CENTRONUCLEAR MYOPATHY AND A NOVEL BIN1 MUTATION. Neurology, 2010, 74, 519-521.	1.5	73
35	Expanding the clinical, pathological and MRI phenotype of DNM2-related centronuclear myopathy. Neuromuscular Disorders, 2010, 20, 229-237.	0.3	100
36	A NEW CENTRONUCLEAR MYOPATHY PHENOTYPE DUE TO A NOVEL DYNAMIN 2 MUTATION. Neurology, 2009, 72, 93-95.	1.5	42

#	Article	IF	Citations
37	Dynamin 2 mutations associated with human diseases impair clathrin-mediated receptor endocytosis. Human Mutation, 2009, 30, 1419-1427.	1.1	76
38	â€œNecklaceâ€•fibers, a new histological marker of late-onset MTM1-related centronuclear myopathy. Acta Neuropathologica, 2009, 117, 283-291.	3.9	106
39	A novel mutation in the dynamin 2 gene in a Charcot-Marie-Tooth type 2 patient: Clinical and pathological findings. Neuromuscular Disorders, 2008, 18, 334-338.	0.3	43
40	Centronuclear myopathy due to a de novo dominant mutation in the skeletal muscle ryanodine receptor (RYR1) gene. Neuromuscular Disorders, 2007, 17, 338-345.	0.3	105
41	C.P.4.11 Ragged red fibres finding in muscle biopsy of dynamin 2-related centronuclear myopathy. Neuromuscular Disorders, 2007, 17, 881-882.	0.3	4
42	Dynamin 2 mutations cause sporadic centronuclear myopathy with neonatal onset. Annals of Neurology, 2007, 62, 666-670.	2.8	136
43	G.P.8 11 Towards the identification of new morphological subtypes of congenital myopathy. Neuromuscular Disorders, 2006, 16, 709-710.	0.3	1
44	G.O. 10 Dynamin 2 mutations and impairment of EGF-induced MAPK activation. Neuromuscular Disorders, 2006, 16, 725-726.	0.3	0
45	Expression of the transcriptional repressor gene myoneurin at the neuromuscular junction, during mouse development and in the adult. Journal of Physiology (Paris), 2006, 99, 1.	2.1	1
46	Characterization of the muscle involvement in dynamin 2-related centronuclear myopathy. Brain, 2006, 129, 1463-1469.	3.7	121
47	Mutations in dynamin 2 cause dominant centronuclear myopathy. Nature Genetics, 2005, 37, 1207-1209.	9.4	390
48	Neuromuscular expression of the BTB/POZ and zinc finger protein myoneurin. Muscle and Nerve, 2004, 29, 59-65.	1.0	15
49	Taurine Down-Regulates Basal and Osmolarity-Induced Gene Expression of Its Transporter, but Not the Gene Expression of Its Biosynthetic Enzymes, in Astrocyte Primary Cultures. Journal of Neurochemistry, 2002, 75, 919-924.	2.1	32
50	Gene expression of the taurine transporter and taurine biosynthetic enzymes in rat kidney after antidiuresis and salt loading. Pflugers Archiv European Journal of Physiology, 2001, 442, 87-95.	1.3	31
51	Characterization of the cDNA Coding for Rat Brain Cysteine Sulfinate Decarboxylase. Journal of Neurochemistry, 2001, 73, 903-912.	2.1	20
52	Gene expression of the transporters and biosynthetic enzymes of the osmolytes in astrocyte primary cultures exposed to hyperosmotic conditions. Glia, 2000, 32, 165-176.	2.5	52
53	Regional Expression and Histological Localization of Cysteine Sulfinate Decarboxylase mRNA in the Rat Kidney¹. Journal of Histochemistry and Cytochemistry, 2000, 48, 1461-1468.	1.3	22
54	Gene expression of taurine transporter and taurine biosynthetic enzymes in brain of rats with acute or chronic hyperosmotic plasma. Molecular Brain Research, 2000, 77, 10-18.	2.5	48

#	Article	IF	Citations
55	Cysteine Sulfinate Decarboxylase (CSD): Molecular Cloning, Sequence and Genomic Expression in Brain. Advances in Experimental Medicine and Biology, 1998, 442, 25-32.	0.8	5